Sanjiv Patel, Relay Therapeutics CEO
September 9, 2024 07:17 AM EDTUpdated 07:45 AM
R&D

Re­lay Ther­a­peu­tics re­ports pos­i­tive PFS da­ta for its PI3Kα in­hibitor com­bo in breast can­cer

Katherine Lewin

News Reporter

Re­lay Ther­a­peu­tics tout­ed pos­i­tive in­ter­im pro­gres­sion-free sur­vival da­ta for its PI3Kα in­hibitor in heav­i­ly treat­ed breast can­cer pa­tients.

In the ear­ly-stage Re­Dis­cov­er tri­al, Re­lay is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times